PAREA regrets FDA refusal of new drug approval for MDMA-assisted therapy for PTSD, which may deprive people with PTSD of an effective treatment option

Written By Tadeusz Hawrot

Read our full news release here

Tadeusz Hawrot
Previous

European psychiatrists’ attitudes toward psychedelics: new study findings
Next

Urgent Need for Collaboration: Addressing Ukraine's Mental Health Crisis Through Psychedelic-Assisted Therapy